Don't Buy Summit Therapeutics Until This Big Thing Happen

Sometimes, everything can seem to be going your way. And then the wheels fall off. That's the situation Summit Therapeutics (NASDAQ: SMMT) finds itself in.Shares of the clinical-stage biotech company skyrocketed 584% last year. The stock more than doubled again by late April 2025. However, Summit subsequently gave up all of its year-to-date gains and then some. What happened? Summit's lead pipeline candidate, ivonescimab, failed to achieve a statistically significant overall survival benefit in a phase 3 clinical study targeting non-small cell lung cancer (NSCLC) conducted by the company's partner, Akeso (OTC: AKES.F). Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool